Stonegate Healthcare Reviews Retinitis Pigmentosa

By: Newsfile

Dallas, Texas--(Newsfile Corp. - December 14, 2022) - Stonegate Healthcare has published a new report on Retinitis Pigmentosa (RP) and the pipeline of products in development. The report follows a recent webinar with ophthalmology experts, including a leading researcher and physician, Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., Chief Development Officer of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman from the Foundation Fighting Blindness.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Retinitis Pigmentosa (RP) is the leading cause of visual disability and blindness in patients under 60.
  • Gene therapies, while promising, are limited in their application by disease stage and genetic mutation.
  • Small molecule photoswitches conversely hold potential to treat mid- to late-stage RP as a stand-alone drug or in combination with gene therapies.

Cannot view this image? Visit:

Click image above to view full announcement.

Stonegate Capital Partners 

Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.


Stonegate Capital Partners
(214) 987-4121

Source: Stonegate, Inc.

To view the source version of this press release, please visit

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.